Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + bevacizumab + irinotecan
- Development stage
- Phase 2
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Toripalimab + bevacizumab + irinotecan is a combination therapy regimen being investigated for the treatment of advanced colorectal cancer, specifically in patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR). The regimen consists of toripalimab, a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor to restore immune response; bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis; and irinotecan, a cytotoxic chemotherapy agent that inhibits DNA topoisomerase I. This combination is being evaluated by Peking University Cancer Hospital & Institute in both neoadjuvant and adjuvant settings, showing high pathological complete response rates in early clinical trials (NCT04988191).
- Other names
- Toripalimab + Bevacizumab + Chemotherapy
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on toripalimab + bevacizumab + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + bevacizumab + irinotecan.